The prolongation of mPFS in the non-EGFR/ALK group could be related to the fact that EGFR-mutant lung cancer patients had prior targeted therapy and therefore, worse performance status and more tumor burden at start of chemoIO therapy. Here, ALK is linked to lung cancer.